Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA-ECP in CTCL and chronic GvHD
NCT03109353Phase 2Completed
- Sponsor
- St. Olavs University Hospital
- Start
- Sep 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 5-aminolevulinic acid in cutaneous T-cell lymphoma (CTCL), chronic graft-versus-host disease (cGVHD), sponsored by St. Olavs University Hospital. Started Sep 2017; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
cutaneous T-cell lymphoma (CTCL)chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03109353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109353.